Suhas Krishna, vice president and head of Digital Health Product Management at Bristol Myers Squibb, commented: “At BMS, we believe that the use of AI to detect key, subtle characteristics in bio signals to aid physicians in the screening, diagnosis, treatment and monitoring of diseases will have a critical and positive impact on patients’ lives. We are excited to continue building momentum in our support of
Viz.ai’s R&D programme. The speed and quality in which this novel AI algorithm & workflow sequencing product was designed, verified, validated and submitted by
Viz.ai for agency review is testament to the ability to drive rapid and meaningful innovation in healthcare.”